PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 478 participants.

Also called NCT07174375

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 478 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07174375
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07174375. Randomized; no masking; primary purpose treatment. Start 2025-09-15 (anticipated); primary completion 2027-12-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PCSK9 Inhibitors in Acute Ischemic Stroke Patients Undergoing Endovascular Therapy
Acronym
PCSK9-PROVE
Condition
Acute Ischemic Stroke
Intervention (Drug)
PCSK9 inhibitor
Lead sponsor
Nanfang Hospital, Southern Medical University (class: other)

Record details

Record id
cardio:ct-nct07174375
Content hash
01ae28bfca806fe7bfb7fa75094d58384aed291eb59d5338305531367980db67